Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
재조합 식물 기반 면역증강제 코로나19 백신의 효능 및 안전성
Clinical Trial
Published on
Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, 치료제,
Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, 치료제,
[키워드] 1:1
95% CI
95% confidence interval
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
adjuvant
adverse event
age
Analysis
AS03
assigned
baseline
candidate vaccine
caused
conducted
coronavirus
coronavirus disease
Coronavirus disease 2019
CoVLP
CoVLP+AS03
determine
disease
dose
effective
Efficacy
Factor
FIVE
incidence
injection
intention-to-treat
intention-to-treat population
Intramuscular injection
Local
median age
Median viral load
Medicago
Mild
moderate
occurred
participant
Participants
participated
Particle
performed
Phase 3
Placebo
placebo group
placebo-controlled trial
plant
plants
polymerase
post-hoc analysis
prefusion
produced
Randomized
receive
recombinant
respiratory
Safety
SARS-CoV-2
sequenced
Sequencing
seronegative
severe acute respiratory syndrome Coronavirus
Severe case
Spectrum
spike glycoprotein
symptomatic
symptomatic COVID-19
symptomatic infection
System
systemic adverse event
systemic adverse events
the median
the placebo group
the vaccine
Trial
two group
two groups
Vaccine
vaccine efficacy
vaccine group
variant
variants
Viral
Viral load
viral sample
Volunteer
[DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial